Literature DB >> 32511134

Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors.

Xu-Feng Zhang1,2, Feng Xue1, Zheng Wu1, Alexandra G Lopez-Aguiar3, George Poultsides4, Eleftherios Makris4, Flavio Rocha5, Zaheer Kanji5, Sharon Weber6, Alexander Fisher6, Ryan Fields7, Bradley A Krasnick7, Kamran Idrees8, Paula M Smith8, Cliff Cho9, Megan Beems9, Yi Lyu1, Shishir K Maithel3, Timothy M Pawlik2.   

Abstract

OBJECTIVE: To improve the prognostic accuracy of the eighth edition of AJCC staging system for pNETs with establishment and validation of a new staging system.
BACKGROUND: Validation of the updated eighth AJCC staging system for pNETs has been limited and controversial.
METHODS: Data from the SEER registry (1975-2016) (n = 3303) and a multi-institutional database (2000-2016) (n = 825) was used as development and validation cohorts, respectively. A mTNM was proposed by maintaining the eighth AJCC T and M definitions, and the recently proposed N status as N0 (no LNM), N1 (1-3 LNM), and N2 (≥4 LNM), but adopting a new stage classification.
RESULTS: The eighth TNM staging system failed to stratify patients with stage I versus IIA, stage IIB versus IIIA, and overall stage I versus II relative to long-term OS in both database. There was a monotonic decrement in survival based on the proposed mTNM staging classification among patients derived from both the SEER (5-year OS, stage I 87.0% vs stage II 80.3% vs stage III 72.9% vs stage IV 57.2%, all P < 0.001), and multi-institutional (5-year OS, stage I 97.6% vs stage II 82.7% vs stage III 78.4% vs stage IV 50.0%, all P < 0.05) datasets. On multivariable analysis, mTNM staging remained strongly associated with prognosis, as the hazard of death incrementally increased with each stage among patients in the 2 cohorts.
CONCLUSION: A mTNM pNETs clinical staging system using N0, N1, N2 nodal categories was better at stratifying patients relative to long-term OS than the eighth AJCC staging.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32511134     DOI: 10.1097/SLA.0000000000004039

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  2 in total

1.  Looking for the right TNM staging system for pancreatic neuroendocrine tumors.

Authors:  Nicola Fazio; Francesca Spada; Emilio Bertani
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

2.  Progress in TNM staging of pancreatic neuroendocrine tumors.

Authors:  Taymeyah Al-Toubah; Jonathan Strosberg
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 7.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.